维生素D补充对早产黑人婴儿反复喘息的影响:D-Wheeze随机临床试验
该随机临床试验纳入300例胎龄28至36周的早产黑人婴儿,在美国4个中心于2013年1月至2016年1月入组,随访至2017年3月。婴儿在达到配方奶或母乳强化剂提供200 IU/d胆钙化醇后,随机接受持续补充400 IU/d胆钙化醇至矫正6月龄(持续补充组,153例)或安慰剂(饮食限制补充组,147例),主要终点为矫正12月龄时反复喘息。持续补充组反复喘息发生率31.1%,饮食限制组41.8%,差异-10.7%(95%CI -27.4%至-2.9%),相对风险0.66(95%CI 0.47至0.94)。上、下呼吸道感染为最常见不良事件,两组上呼吸道感染发生率54.9% vs 56.5%(差异-1.6%,95%CI -17.1%至7.0%),下呼吸道感染21.6% vs 25.2%(差异-3.6%,95%CI -16.4%至4.4%)。
要点
- 持续补充组反复喘息31.1%,饮食限制组41.8%,差异-10.7%(95%CI -27.4%至-2.9%),相对风险0.66(95%CI 0.47至0.94)。
- 上呼吸道感染:持续补充组54.9%(84/153) vs 饮食限制组56.5%(83/147),差异-1.6%(95%CI -17.1%至7.0%)。
- 下呼吸道感染:持续补充组21.6%(33/153) vs 饮食限制组25.2%(37/147),差异-3.6%(95%CI -16.4%至4.4%)。
- 277/300例(92.3%)完成试验;平均胎龄33周,中位出生体重1.9 kg。
- 作者结论:持续补充维生素D较饮食限制补充降低矫正12月龄反复喘息风险;需未来研究理解机制及长期效应。
适用人群与场景
- 胎龄28至36周的早产黑人婴儿,于新生儿重症监护室或新生儿 nursery 出院前入组。
- 在美国4个中心于2013年1月至2016年1月入组,随访至2017年3月。
- 随机化按中心和母乳暴露分层。
处置流程与药物剂量
- 入组后先接受开放标签多种维生素,直至从配方奶或添加至母乳的强化剂中摄入200 IU/d胆钙化醇。
- 随后持续补充组接受400 IU/d胆钙化醇至矫正6月龄(按早产矫正),饮食限制补充组接受安慰剂。
研究设计与关键结果
- 随机临床试验,纳入300例早产黑人婴儿,持续补充组153例,饮食限制补充组147例。
- 主要终点:矫正12月龄反复喘息,持续补充组31.1% vs 饮食限制组41.8%,差异-10.7%(95%CI -27.4%至-2.9%),相对风险0.66(95%CI 0.47至0.94)。
- 上呼吸道感染:持续补充组54.9%(84/153) vs 饮食限制组56.5%(83/147),差异-1.6%(95%CI -17.1%至7.0%)。
- 下呼吸道感染:持续补充组21.6%(33/153) vs 饮食限制组25.2%(37/147),差异-3.6%(95%CI -16.4%至4.4%)。
- 277/300例(92.3%)完成试验;平均胎龄33周,中位出生体重1.9 kg。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:作者指出需未来研究以更好理解维生素D补充对早产儿喘息的作用机制及长期效应。
对床旁实践的改变
- 对于胎龄28至36周的早产黑人婴儿,在达到从配方奶或母乳强化剂摄入200 IU/d胆钙化醇后,持续补充400 IU/d至矫正6月龄较安慰剂降低矫正12月龄反复喘息风险(31.1% vs 41.8%,RR 0.66)。
- 上、下呼吸道感染为最常见不良事件,两组上呼吸道感染(54.9% vs 56.5%)及下呼吸道感染(21.6% vs 25.2%)差异未达统计学显著。
- 作者认为需未来研究以更好理解机制及长期效应。
指南或共识出处
- D-Wheeze随机临床试验(ClinicalTrials.gov标识NCT01601847)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Black infants born preterm face high rates of recurrent wheezing throughout infancy. Vitamin D supplementation has the potential to positively or negatively affect wheezing through modulation of the pulmonary and immune systems.
OBJECTIVE: To assess the effectiveness of 2 vitamin D dosing strategies in preventing recurrent wheezing.
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial enrolled 300 black infants born at 28 to 36 weeks' gestation between January 2013 and January 2016 at 4 sites in the United States, and followed them up through March 2017. Randomization was stratified by site and maternal milk exposure.
INTERVENTIONS: Patients were enrolled prior to discharge from the neonatal intensive care unit or newborn nursery and received open-label multivitamin until they were consuming 200 IU/d of cholecalciferol from formula or fortifier added to human milk, after which they received either 400 IU/d of cholecalciferol until 6 months of age adjusted for prematurity (sustained supplementation) or placebo (diet-limited supplementation). One-hundred fifty three infants were randomized to the sustained group, and 147 were randomized to the diet-limited group.
MAIN OUTCOMES AND MEASURES: Recurrent wheezing by 12 months' adjusted age was the primary outcome.
RESULTS: Among 300 patients who were randomized (mean gestational age, 33 weeks; median birth weight, 1.9 kg), 277 (92.3%) completed the trial. Recurrent wheezing was experienced by 31.1% of infants in the sustained supplementation group and 41.8% of infants in the diet-limited supplementation group (difference, -10.7% [95% CI, -27.4% to -2.9%]; relative risk, 0.66 [95% CI, 0.47 to 0.94]). Upper and lower respiratory tract infections were among the most commonly reported adverse events. Upper respiratory infections were experienced by 84 of 153 infants (54.9%) in the sustained group and 83 of 147 infants (56.5%) in the diet-limited group (difference, -1.6% [95% CI, -17.1% to 7.0%]). Lower respiratory infections were experienced by 33 of 153 infants (21.6%) in the sustained group and 37 of 147 infants (25.2%) in the diet-limited group (difference, -3.6% [95% CI, -16.4% to 4.4%]).
CONCLUSIONS AND RELEVANCE: Among black infants born preterm, sustained supplementation with vitamin D, compared with diet-limited supplementation, resulted in a reduced risk of recurrent wheezing by 12 months' adjusted age. Future research is needed to better understand the mechanisms and longer-term effects of vitamin D supplementation on wheezing in children born preterm.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01601847.
参考来源
- Hibbs AM, Ross K, Kerns LA, et al. Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial. JAMA. 2018. PMID: 29800180. doi:10.1001/jama.2018.5729
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。